What should I do if I become drug-resistant after taking Nivolumab?

The active ingredient in Nivolumab (Nivolumab) is a monoclonal antibody, a protein designed to attach to the PD-1 receptor on immune system cells called T cells. Cancer cells can produce proteins (PD-L1 and PD-L2) on their surface that attach to this receptor and shut down the activity of T cells, preventing them from attacking the cancer. By attaching to the receptor, nivolumab prevents PD-L1 and PD-L2 from shutting down T cells, thereby improving the immune system's ability to kill cancer cells.

If a patient develops resistance to nivolumab, doctors can consider switching to other treatment options, such as combining it with other drugs or choosing other immune checkpoint inhibitors. This improves treatment response and survival. Combining nivolumab with chemotherapy drugs may improve the therapeutic effect of nivolumab. Chemotherapy can change the tumor microenvironment and increase the ability of immune cells to attack tumors, thereby enhancing the efficacy of nivolumab. For patients with strong drug resistance, participating in relevant clinical trials may be an option. Clinical trials offer new treatment strategies and drugs that may respond to drug resistance.

The generic drug Nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around RMB 4,000. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.